Innovation1 Biotech Inc.
Innovation1 Biotech Inc.
Your view on IVBT
Overview
What the company does, where it operates, and who runs it.
About Innovation1 Biotech Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Francis Knuettel
- Headquarters
- 40 Wall Street, Somerville, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Francis Knuettel
- Headquarters
- 40 Wall Street, Somerville, NY, US
Innovation1 Biotech Inc., a drug discovery company, focuses on the development of modified schedule 1 molecules of botanical origin in the United States.
Its portfolio includes five proprietary fully synthetic preclinical prodrugs addressing independent clinical indications comprising a mushroom-derived psychedelic molecule for treatment of post-traumatic stress disorder and depression; a novel cannabinoid and tree bark derived psychedelic for treatment of addiction; and three additional cannabinoid prodrugs addressing clinical indications of refractory pediatric epilepsy, hypertrophic scarring, and ocular inflammation.
The company was formerly known as Gridiron BioNutrients, Inc. and changed its name to Innovation1 Biotech Inc. in March 2022. Innovation1 Biotech Inc. was founded in 2014 and is headquartered in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Innovation1 Biotech Inc., and the rating behind it. IVBT last traded at $0.0002; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Innovation1 Biotech Inc.. Starting points for Innovation1 Biotech Inc.: EPS -$0.30, beta 5.83 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Innovation1 Biotech Inc.. Innovation1 Biotech Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Innovation1 Biotech Inc.. Trailing twelve-month EPS for Innovation1 Biotech Inc. stands at -$0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Innovation1 Biotech Inc.. Innovation1 Biotech Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Innovation1 Biotech Inc. valued side by side against its closest peers. Innovation1 Biotech Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Innovation1 Biotech Inc., and how their positions are changing. At a $4,494 market value, institutional positions materially move Innovation1 Biotech Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Innovation1 Biotech Inc. executives and directors. Shares of Innovation1 Biotech Inc. have traded between $0.0002 and $0.0050 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Innovation1 Biotech Inc.. Innovation1 Biotech Inc. is a $4,494 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Innovation1 Biotech Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Innovation1 Biotech Inc.. Coverage tracks Innovation1 Biotech Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.